Champions Oncology (NASDAQ:CSBR) Issues Earnings Results

Champions Oncology (NASDAQ:CSBR) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02), Zacks reports. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%.

Champions Oncology Stock Performance

NASDAQ:CSBR traded up $0.09 during mid-day trading on Thursday, hitting $5.10. 14,233 shares of the stock were exchanged, compared to its average volume of 8,371. The firm’s 50-day simple moving average is $5.44 and its 200 day simple moving average is $5.82. The stock has a market capitalization of $70.99 million, a price-to-earnings ratio of -63.75 and a beta of 0.40. Champions Oncology has a fifty-two week low of $4.83 and a fifty-two week high of $8.74.

Institutional Trading of Champions Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in shares of Champions Oncology in the second quarter valued at approximately $103,000. Essex Investment Management Co. LLC bought a new position in Champions Oncology during the 4th quarter worth $126,000. Jane Street Group LLC bought a new position in Champions Oncology during the 1st quarter worth $200,000. Goldman Sachs Group Inc. acquired a new position in Champions Oncology in the 1st quarter valued at $201,000. Finally, Acadian Asset Management LLC lifted its position in shares of Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 8,814 shares during the period. Institutional investors and hedge funds own 41.30% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.